{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-25-000003","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.684817+00:00","generated_at":"2026-05-26T05:19:18.260987+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ligand leads $75M royalty financing for Castle Creek's D-Fi gene therapy Phase 3 trial","bullets":["Ligand invested $50M and led syndicate of co-investors totaling $75M for high single-digit royalty on D-Fi worldwide sales.","Castle Creek to use funds for Phase 3 trial of D-Fi (gene therapy) for dystrophic epidermolysis bullosa (DEB).","Ligand also acquired $8.3M subordinated promissory note for $1.8M, due upon FDA approval of D-Fi.","Co-investors include Paragon Biosciences, Valor Equity Partners, and XOMA Royalty Corp. (Nasdaq: XOMA).","Warrants to purchase Series D-1 Preferred Shares exercisable until 2035."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-25-000003","json":"https://secwatch.observer/filing/0000886163-25-000003.json","markdown":"https://secwatch.observer/filing/0000886163-25-000003.md","text":"https://secwatch.observer/filing/0000886163-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000003/0000886163-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616325000003/lgnd-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:19:18.260987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}